EGI
RCUS icon

EAM Global Investors’s Arcus Biosciences RCUS Stock Holding History

EAM Global Investors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-49,498
Closed -$2M – 275
2021
Q4 		$2M Buy
+49,498
New +$1.92M 0.36% 156
2020
Q3 		– Sell
-36,915
Closed -$913K – 173
2020
Q2 		$913K Buy
+36,915
New +$996K 0.41% 115

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

EAM Global Investors's RCUS Position: Q1 2022 in Review

EAM Global Investors sold out of Arcus Biosciences (RCUS) in Q1 2022, closing a stake of 49,498 shares — an estimated $2M sold.

EAM Global Investors first reported a position in RCUS in Q2 2020 and held it in 2 quarters. The position peaked at $2M in Q4 2021. 157 funds tracked by Wall St. Rank hold RCUS as of Q1 2022.

  • EAM Global Investors reported no remaining Arcus Biosciences position as of Q1 2022 after selling out during the quarter.
  • EAM Global Investors sold 49,498 Arcus Biosciences shares in Q1 2022, an estimated $2M.
  • EAM Global Investors first reported a position in Arcus Biosciences in Q2 2020 and held it in 2 quarters.
  • EAM Global Investors's Arcus Biosciences position peaked at $2M in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2022.

Based on EAM Global Investors's 13F filing for Q1 2022, filed 13 May 2022.